Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2015

View Archived Issues

Evestra receives convertible loan from Gedeon Richter to fund women's health pipeline

Palatin Technologies presents concordance analysis of diagnostic criteria for female sexual disorder

Study tests effects of alprostadil cream on genital blood flow

New softgel capsule technology provides better patient experience

Anti-MAdCAM antibody efficacy results for ulcerative colitis and Crohn's disease

Celimmune founded to develop new therapeutics for celiac and other autoimmune diseases

Eli Lilly and Incyte report phase III data for baricitinib in rheumatoid arthritis

Arrowhead begins phase I trial of ARC-AAT

Rindopepimut receives FDA breakthrough therapy designation in glioblastoma

Novocure enrolls first patient in phase II STELLAR trial

Foundation Medicine and H3 Biomedicine to develop precision therapies for cancer

FDA approves Dymista for use in children with seasonal allergic rhinitis

New guanylyl cyclase activators disclosed by Bayer

Rigel and BMS collaborate on TGF-beta receptor inhibitors for cancer

Gruenenthal divulges novel PDE4B inhibitors

Merck & Co. patents new ROMK channel blockers

Retrospective analysis shows overall survival benefit for ThermoDox in a subgroup of HCC patients

Sunshine Lake Pharma discloses new 5-HT reuptake inhibitors

Boehringer Ingelheim presents new ROR-gamma modulators

PMO targeting Ebola virus VP24 protects nonhuman primates

Takeda to acquire select portfolio from Neutec

FDA approves Novartis's panobinostat for multiple myeloma

ValiRx reports preliminary results from a phase I/II trial of VAL-201 in men with prostate cancer

FDA accepts Taiho's NDA for TAS-102 for refractory metastatic colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...